Managing Gynecomastia on Testosterone Cypionate: The HealthRX.com Step-by-Step Protocol

Why testosterone cypionate can cause it

Testosterone is converted to estradiol by the enzyme aromatase, which is expressed in the testis and in other male tissues [4]. Estrogens stimulate breast tissue growth and androgens inhibit it, and most gynecomastia results from deficient androgen action or excessive estrogen action in the breast [3]. The estrogen-to-androgen balance, not testosterone acting on breast tissue directly, is what drives the tissue [3].

In the Depo-Testosterone label (testosterone cypionate, intramuscular), gynecomastia appears in the adverse reactions list, and the warnings state that it may develop and occasionally persists in patients being treated for hypogonadism [1]. The label gives no frequency [1].

Does it settle on its own?

The 2019 guideline recommends watchful waiting after an underlying condition is treated or a substance linked to gynecomastia is discontinued [2]. It also says testosterone treatment should be offered to men with proven testosterone deficiency [2]. The label does not describe what happens to gynecomastia after an injection series ends [1].

How gynecomastia is evaluated

The guideline sets three goals for assessment: find an underlying condition, find reversible causes such as drugs, and separate gynecomastia from breast cancer [2]. It recommends a thorough history and examination of the breasts and genitalia, including testicular ultrasound, and says laboratory tests may be part of the evaluation: testosterone, estradiol, sex hormone-binding globulin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone, prolactin, human chorionic gonadotropin, alpha-fetoprotein, and liver and renal function tests [2]. It says breast imaging may be used when the examination is equivocal, and that a suspicious lesion should go directly to core needle biopsy [2].

Male breast cancer is much less common than gynecomastia, and the two can usually be told apart by careful physical examination [3]. The Depo-Testosterone label lists carcinoma of the breast in men as a contraindication [1].

Do aromatase inhibitors and SERMs work here?

The guideline says SERMs, aromatase inhibitors and non-aromatizable androgens are not justified in general for gynecomastia [2].

Tamoxifen and raloxifene were studied for persistent pubertal gynecomastia, not for gynecomastia arising during testosterone cypionate treatment [5]. In that retrospective chart review of 38 patients, some of whom received reassurance alone, 3 to 9 months of tamoxifen reduced breast nodule diameter by a mean of 2.1 cm and raloxifene by 2.5 cm; some improvement occurred in 86% on tamoxifen and 91% on raloxifene, and a reduction of more than 50% was more common with raloxifene (86%) than tamoxifen (41%) [5]. A separate review notes that tamoxifen has been tried in adolescents, while letrozole and anastrozole have not been consistently useful in that age group [6].